SRR5088835
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.500
- INTERFERON_ALPHA_RESPONSE+0.500
- INTERFERON_GAMMA_RESPONSE+0.500
- IL6_JAK_STAT3_SIGNALING+0.400
- E2F_TARGETS+0.300
- G2M_CHECKPOINT+0.300
- IL2_STAT5_SIGNALING+0.200
- INFLAMMATORY_RESPONSE+0.200
- PI3K_AKT_MTOR_SIGNALING+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.500
- PROTEIN_SECRETION-0.500
- ADIPOGENESIS-0.400
- ANGIOGENESIS-0.400
- CHOLESTEROL_HOMEOSTASIS-0.400
- COAGULATION-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- FATTY_ACID_METABOLISM-0.400
- GLYCOLYSIS-0.400
- PANCREAS_BETA_CELLS-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088834 | — | — | 0.939 |
| 2 | SRR5088892 | — | — | 0.921 |
| 3 | SRR6013475 | — | cohortMD2 | 0.908 |
| 4 | 41b25e1d-b18b-427f-906c-b16f29056775 | — | — | 0.881 |
| 5 | AUR-AG0J-TTP1-A-1-0-R-A741-41 | — | D | 0.853 |
| 6 | TCGA-B6-A0RT-01A-21R-A084-07 | — | D | 0.851 |
| 7 | TCGA-85-A4PA-01A-11R-A24Z-07 | — | cohortMD2 | 0.850 |
| 8 | AUR-AF95-TTP1-A-1-0-R-A741-41 | — | D | 0.849 |
| 9 | GSM5359433 | — | — | 0.847 |
| 10 | NALM1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.841 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |